期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 129, 期 3, 页码 S65-S87出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2011.12.986
关键词
Spirometry; airway responsiveness; peak expiratory flow monitoring; lung volumes; gas exchange
资金
- National Institute of Allergy and Infectious Diseases
- National Heart, Lung, and Blood Institute
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute of Environmental Health Sciences
- Agency for Healthcare Research and Quality
- Merck Childhood Asthma Network
- Robert Wood Johnson Foundation
- US Environmental Protection Agency
- GlaxoSmithKline
- Boehringer-Ingelheim
- Merck
- Forest
- NIH
- American Lung Association
- Asthmatx
- Eumedics
- Novartis
- Genentech
- MedImmune
- Sanofi-Aventis
- Amgen
Background: Outcomes of pulmonary physiology have a central place in asthma clinical research. Objective: At the request of National Institutes of Health (NIH) institutes and other federal agencies, an expert group was convened to provide recommendations on the use of pulmonary function measures as asthma outcomes that should be assessed in a standardized fashion in future asthma clinical trials and studies to allow for cross-study comparisons. Methods: Our subcommittee conducted a comprehensive search of PubMed to identify studies that focused on the validation of various airway response tests used in asthma clinical research. The subcommittee classified the instruments as core (to be required in future studies), supplemental (to be used according to study aims and in a standardized fashion), or emerging (requiring validation and standardization). This work was discussed at an NIH-organized workshop in March 2010 and finalized in September 2011. Results: A list of pulmonary physiology outcomes that applies to both adults and children older than 6 years was created. These outcomes were then categorized into core, supplemental, and emerging. Spirometric outcomes (FEV1, forced vital capacity, and FEV1/forced vital capacity ratio) are proposed as core outcomes for study population characterization, for observational studies, and for prospective clinical trials. Bronchodilator reversibility and prebronchodilator and postbronchodilator FEV1 also are core outcomes for study population characterization and observational studies. Conclusions: The subcommittee considers pulmonary physiology outcomes of central importance in asthma and proposes spirometric outcomes as core outcomes for all future NIH-initiated asthma clinical research. (J Allergy Clin Immunol 2012; 129: S65-87.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据